Daily Stock List
Rafarma Pharmaceuticals, Inc. (RAFA)
FeedBlitz and Stocks That Move reported recently on Rafarma Pharmaceuticals, Inc. (RAFA), PennyStocks24, Real Pennies, Penny Stock Rumble, Greenbackers, WallstreetSurfers did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
With U.S. headquarters in Sandy, Utah, and a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals, Inc. is a multi-product pharmaceutical company. They produce generic antibiotics and specialty pharmaceuticals in addition to their own line of proprietary products that have approval from the Ministry of Health of the Russian Federation. Rafarma Pharmaceuticals lists on the OTC Pink Current Information.
The Company's corporate mission is to work with the backing of aggressive federal initiatives to fast track the modernization of Russia's pharmaceutical industry. Rafarma owns and operates a multi-profile pharmaceutical plant that can produce all kinds and forms of medical drugs in a range of pharmacological groups. The construction of the plant was in the territory of a special industrial economic zone in Terbuny of the Lipetsk region of Russia. The Zdorovie Foundation initiated the project.
Rafarma Pharmaceuticals' plan is to use their new Terbuny facility to produce the Company's own pharmaceutical products. Ten are currently undergoing the approval process; seven have already completed clinical trials. Twelve have their foundation on the Company's advanced proprietary technology.
The Company has their line of their F-Zed based products, and F-Zed products clinical Studies. Rafarma's products include Benzalconium Fluoride, Benzomet, Benzolete, and Benzoteks. Rafarma is on track to saturate the Russian market as a European-based specialist pharmaceutical producer. In addition, Rafarma is securing their foothold to enter global markets such as Brazil and the Southeast Asian sub-continent.
This past February, Rafarma Pharmaceuticals announced that they received the general license for pharmaceutical products and began the manufacturing of three new products. The general license was one of the final steps required to open the new plant in Terbuny. The three new products are Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin.
In April, Rafarma Pharmaceuticals announced that ZAO "Rafarma" registered (MHH) Ceftriaxone, a third-generation cephalosporin antibiotic, as a medication under international unpatented label. Ceftriaxone is most often used in combination for the treatment of pneumonia, bacterial meningitis, gonorrhea, and in pediatrics for the prevention of sepsis.
Rafarma Pharmaceuticals, Inc. (RAFA), closed Tuesday's trading session at $0.235, up 30.56%, on 185,258 volume with 39 trades. The average volume for the last 60 days is 44,613 and the stock's 52-week low/high is $0.041/$0.98.
Tauriga Sciences, Inc. (TAUG)
PennyStocks24, Winston Small Cap, Winning Penny Stock Picks, Whisper from Wall Street, WePickPennyStocks, WallstreetSurfers, Super Nova Stock Picks, Super Hot Penny Stocks, StockMister, StockHideout, Stock Twiter, Stock Shock and Awe, and Stock Roach reported recently on Tauriga Sciences, Inc. (TAUG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Tauriga Sciences, Inc. is a life sciences company focusing on proprietary biotherapeutics and diagnostics, novel medical devices and consumer healthcare. Their business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. The Company previously went by the name Immunovative, Inc. They changed their name to Tauriga Sciences, Inc. in April of this year.
The corporate mission of Tauriga Sciences is to acquire a diversified portfolio of medical technologies. Their goal is to provide financial and human capital resources, to unlock significant value for shareholders.
Yesterday, Green Innovations Ltd. (GNIN) announced that on May 31, 2013, their wholly owned subsidiary, Green Hygienics, Inc. executed an exclusive North American licensing agreement with Tauriga Sciences for the commercial launch of hospital grade products. These include 100 percent tree-free bamboo-based biodegradable disinfectant wipes. The terms of the Licensing Agreement provide for an equal share of the profits between the two companies.
Currently, Tauriga Sciences and Green Innovations anticipate having the first hospital grade products available for sale to wholesalers, retailers, and for direct purchase during the Fall of 2013.
Today, Tauriga Sciences announced the public launch of Cambridge, Massachusetts-based Constellation Diagnostics, Inc., developer of a camera-based technology with the objective of preventing skin cancer via early detection. Tauriga Sciences announced a Memorandum of Understanding (MOU) with Constellation Diagnostics on May 2, 2013. Tauriga can earn an equity stake in Constellation of up to 35 percent; as earlier disclosed the Company has made an initial investment. Constellation Diagnostics is developing a novel, imaging-based diagnostic technology for use in predictive and preventative oncology.
Tauriga Sciences' Chief Operating Officer, Dr. Stella Sung, commented, "Constellation's novel imaging system has relevance to millions of people worldwide who are at risk for skin cancer. Skin cancer is the most common of all cancers and represents nearly half of all cancers in the United States. We are excited about the potential of this dermatologist-endorsed product to save many lives through comprehensive and early tracking and detection."
Tauriga Sciences, Inc. (TAUG), closed Tuesday's trading session at $0.0815, up 8.67%, on 948,898 volume with 71 trades. The average volume for the last 60 days is 253,018 and the stock's 52-week low/high is $0.04/$0.324.
Richfield Oil & Gas Company (ROIL)
RedChip reported recently on Richfield Oil & Gas Company (ROIL), FeedBlitz did earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Listed on the OTCQX U.S. Premier, Richfield Oil & Gas Company engages in oil and gas exploration and development in the western U.S. The Company has been successful in developing producing oil wells and is active in acquiring oil and gas interests for developing commercially productive wells on those interests. Richfield Oil & Gas has all of their operations in the United States. The Company is based in Salt Lake City, Utah.
Richfield Oil & Gas' portfolio of oil and gas properties is in Utah, Wyoming, Kansas and Oklahoma. These properties encompass three major geographic areas of operation. These include the Mid-Continent, the Utah-Wyoming Overthrust, as well as the Central Utah Overthrust. These projects are made of a mix of low risk development, and stable production in Kansas and Wyoming, along with the high-risk, large upside potential in The Rocky Mountain States.
The Company's Mid-Continent operations cover approximately 3,000 acres in six fields in central and southern Kansas, and northern Oklahoma. However, they are principally in the Central Kansas Uplift (CKU).
The Utah-Wyoming Overthrust is the region covering northeast Utah and southwest Wyoming. Richfield has accumulated acreage covering two separate structural highs in the Jurassic Nugget Sandstone. Several other potentially productive formations have had favorable test results throughout the region. In the Central Utah Overthrust, Richfield Oil & Gas has three projects. These are the Liberty Prospect, the HUOP Freedom Trend Prospect, and the Independence Prospect.
Richfield's plan is to develop their Proved and Probable Reserves in Kansas, Wyoming and Oklahoma. In addition, the Company is focusing on exploring and proving out their Independence, HUOP Freedom Trend and Liberty prospects in Central Utah. Furthermore, they are working to leverage their extensive research base to acquire additional acreage strategically in the Mid-Continent, the Central Utah Overthrust and the Utah-Wyoming Overthrust. Moreover, Richfield is concentrating on maintaining a low overall cost structure and preserving financial flexibility.
At the end of April, Richfield Oil & Gas announced that they engaged Baker Hughes GMI Geomechanics Services (GMI) to lead a team of technical consultants to evaluate the Liberty #1 Well. This is to determine the next phase of operations, anticipated to result in commercial production.
Richfield's interest in the Liberty #1 Well, which is contained in the Liberty Prospect, is 64.29 percent working interest (WI) before payout (BPO) and 50.56 percent WI after payout (APO). In the remaining Liberty Prospect, which incorporates 1,185 acres, the Company owns a 74.69 percent WI BPO and a 59.56 percent WI APO. The Liberty Prospect is on the Paxton Thrust in the northernmost part of the Central Utah Overthrust in Juab County, Utah.
Richfield Oil & Gas Company (ROIL), closed Tuesday's trading session at $0.75, even for the day, on 113,725 volume with 22 trades. The average volume for the last 60 days is 18,349 and the stock's 52-week low/high is $0.64/$3.50.
e.Digital Corp. (EDIG)
FeedBlitz and Greenbackers reported previously on e.Digital Corp. (EDIG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
e.Digital Corp. engages in the development and marketing of the eVU® mobile entertainment system to the travel industry in the United States and worldwide. The Company pioneered dedicated portable in-flight entertainment systems. More than 30 airlines have made e.Digital powered products their in-flight entertainment choice. e.Digital has their corporate headquarters in San Diego, California. The Company's shares trade on the OTC Markets' OTCQB.
The Company has created foundational technologies that are at the core of wireless headset, digital audio/video recorder and portable music player markets. e.Digital's Flash-R™ patent portfolio consists of fundamental technology related to the use of flash memory in the large and growing portable electronic products market. e.Digital introduced the first portable recorder with removable flash memory in 1993.
Moreover, the Company's eVU® is a studio-approved, portable media player. It uses proprietary encryption technology to safeguard content on internal storage devices. e.Digital also has their Nunchi® offering. This technology retrieves data from a variety of existing mobile phone sensors and uses this information to recognize, understand and affect interactions among people.
Last month, e.Digital announced that the Company's attorneys successfully secured new patent license agreements for technologies embodied in their Flash-R™ patent portfolio. The arrangements represent the first license agreements since resolution of the Eastern District of Texas and Colorado court actions. The Flash-R™ portfolio is protected through the years 2014 - 2016.
Recently, e.Digital announced that they entered into a license and settlement agreement with Creative Labs. Under the terms of the confidential agreement, Creative Labs obtained a license and release on e.Digital's Flash-R™ patent portfolio and paid e.Digital a one-time license fee.
Mr. Fred Falk, e.Digital's President and Chief Executive Officer, said, "We are pleased to have Creative join our family of Flash-R portfolio licensees. Creative joins the growing list of Flash-R portfolio licensees, which includes Panasonic, Samsung, Olympus, HTC and other world recognized manufacturing companies. With the assistance of our law firm, Handal & Associates, this now brings the total number of license and settlement agreements during 2013 to five as we aggressively pursue our monetization efforts."
e.Digital Corp. (EDIG), closed Tuesday's trading session at $0.10, down 1.96%, on 285,340 volume with 27 trades. The average volume for the last 60 days is 171,343 and the stock's 52-week low/high is $0.01/$0.197.
Dyadic International, Inc. (DYAI)
TheStockAdvisors, TopStockAnalysts, Investor Update, BullRally, Whiskey & Gunpowder, and Penny Sleuth reported previously on Dyadic International, Inc. (DYAI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Dyadic International, Inc. is a global biotechnology company that lists on the OTC Pink Current Information. The Company focuses on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform. The basis of it is on their patented and proprietary C1 fungus that enables the development and large-scale manufacture of low cost proteins and enzymes for diverse market opportunities.
Dyadic International has their headquarters in Jupiter, Florida. The Company has their main research and development operations in The Netherlands. They currently sell more than 55 liquid and dry enzyme products to over 150 industrial customers in approximately 50 countries for a wide spectrum of industries. These include biofuels, bio-based chemicals, biopharmaceuticals, animal health and nutrition, pulp & paper, textiles, food and beverage, and nutraceuticals.
Pertaining to their C1 platform technology, it can also be used to screen for the discovery of novel genes and proteins. The Company actively pursues licensing arrangements and other commercial opportunities to take advantage of the value of these technologies through providing their partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes that these technologies help produce. C1 addresses the critical bottlenecks of protein discovery, development, scale-up and commercialization. C1 enables new product introduction with less time, cost and risk.
Recently, BASF (BAS.DE) and Dyadic International announced that they entered into a non-exclusive worldwide research and license agreement. Under the terms of the agreement, BASF will be able to use Dyadic's patented and proprietary C1 platform technology to develop, produce, distribute and sell industrial enzymes in certain fields for an array of applications. BASF will fund research and development at Dyadic's research lab in The Netherlands. In addition to this funding, BASF has agreed to pay Dyadic International a $6 million upfront license fee, and certain research and commercial milestone fees, and royalties upon commercialization. BASF is the world's leading chemical company. Their portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas.
Last week, Dyadic International announced that their President and Chief Executive Officer, Mr. Mark Emalfarb, would present at the World Biotechnology Congress 2013 in Boston, Massachusetts, and the BIO World Congress on Industrial Biotech in Montreal, Quebec. Mr. Emalfarb's presentation at the World Biotechnology Congress will take place on June 6, from 11:20 – 11:40 a.m. EDT at the John B. Hynes Veterans Memorial Convention Center. At the BIO World Congress on Industrial Biotech on June 18, he will participate on a panel called "Global Benefits for Synthetic Biology Tools" from 10:30 a.m. – 12:00 p.m. EDT at the Palais des Congres de Montreal.
Dyadic International, Inc. (DYAI), closed Tuesday's trading session at $1.97, down 0.51%, on 41,192 volume with 24 trades. The average volume for the last 60 days is 33,836 and the stock's 52-week low/high is $0.90/$2.25.
PolyMet Mining Corp. (POM.TO)
Today we are reporting on PolyMet Mining Corp. (POM.TO), here at the QualityStocks Daily Newsletter.
PolyMet Mining Corp. is a mine development company that owns 100 percent of Poly Met Mining, Inc., a Minnesota corporation. Poly Met Mining, Inc. controls 100 percent of the NorthMet copper-nickel-precious metals ore body through a long-term lease. Poly Met Mining also owns 100 percent of the Erie Plant, a large processing facility situated approximately six miles from the ore body in the established mining district of the Mesabi Range in northeastern Minnesota.
PolyMet has their corporate headquarters in Toronto, Ontario. The Company has executive offices in St. Paul, as well as operational headquarters in Hoyt Lakes, Minnesota. The Company's team includes many third- and fourth-generation miners. PolyMet's shares trade on the Toronto Stock Exchange.
Poly Met Mining, Inc. has completed their Definitive Feasibility Study. They are seeking environmental and operating permits to enable them to begin production. The expectation is that the NorthMet project will require approximately two million hours of construction labor, creating approximately 360 long-term jobs.
The NorthMet project is part of northeastern Minnesota's Duluth Complex. This Complex is one of the world's largest undeveloped deposits of copper, nickel and other precious metals. PolyMet proposes a mining process that will use advanced science and engineering to recover copper, nickel and precious metals. The NorthMet project features two major assets that together cover approximately 16,700 acres, or 26 square miles.
Moreover, the Company's Erie Plant includes crushing and milling facilities, electric substations, tailings facilities, an office building, a road and rail that connects to the NorthMet deposit, and other essential infrastructure. The processing plant can produce 100,000 tons of ore per day. The design of the NorthMet project is to process 32,000 tons of ore per day, using less than one third of the Erie Plant's capacity.
Concerning Community Relations, more than 1,000 people attended the PolyMet open house at the Arena in Hoyt Lakes on May 29, 2013. Booths described the environmental review and permitting process, mining and processing, plans to protect the environment, technology to monitor and maintain air and water quality, and job opportunities and the economic benefit of the project.
Concerning their Environmental Review, on May 13, 2013, PolyMet reported that ERM, the independent EIS Contractor, completed drafting the NorthMet preliminary supplemental draft Environmental Impact Statement (EIS).
PolyMet Mining Corp. (POM.TO), closed Tuesday's trading session at $1.08, down 0.92%, on 51,300 volume. The stock's 52-week low/high is $0.72/$1.27.
QuantRx Biomedical Corp. (QTXB)
Stock Traders Chat, Mega Stock Picks, Penny Stock Fever, Micro Cap Momentum, and Epic Stock Picks reported previously on QuantRx Biomedical Corp. (QTXB), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
QuantRx Biomedical Corp. concentrates on the development and commercialization of diagnostic products for the global healthcare industry. The Company has developed, and ultimately intends to commercialize, their unique PAD based products for the Over-The-Counter (OTC) and laboratory markets based on their patented technology platforms. Additionally, they intend to commercialize their genomic diagnostics, based on their patented PadKit technology for the global healthcare industry. QuantRx Biomedical lists on the OTC Markets' OTCQB.
QuantRx Biomedical's business and operating plan is currently focusing on the commercialization of their PAD technology either directly or by way of a joint venture or other relationship. For the period ending March 31, 2013, QuantRx had minority investments in Genomics USA, Inc. (GUSA). At present, the Company is evaluating their minority equity interest in GUSA with the objective of extracting the value of such investment for the benefit of the Company and their shareholders.
QuantRx Biomedical formed a wholly owned subsidiary, QX Labs, Inc., on June 20, 2012, to convey and transfer to QX all intellectual property (IP) and assets related to the Company's diagnostic testing business. The basis of the Diagnostic Business is mainly on their proprietary PadKit technology. The Company believes this technology provides a patented platform technology for genomic diagnostics, including fetal genomics.
The Company's other business line (following the transfer of the Diagnostics Business to QX) will consist of their OTC business. This includes the InSync feminine hygienic interlabial pad, the Unique pad for hemorrhoid application, and other treated miniforms. It will also consist of established and continuing licensing relationships related to the OTC Business. QuantRx Biomedical's Management believes the creation of QX permits the Company to explore different options more efficiently to maximize the value of the Diagnostics Business and the OTC Business.
The present focus of QuantRx Biomedical is to develop a financing and operating plan to take advantage of their broad-based IP and patent portfolio to develop new and innovative diagnostic products. Additionally, their focus is to commercialize their OTC Business and their Diagnostics Business directly or through joint ventures, mergers or similar transactions intended to capitalize on commercial opportunities presented by each of the Businesses. Furthermore, they are focusing on contracting manufacturing to third parties while maintaining control over the manufacturing process; and maximizing the value of the Company's investments in non-core assets, including the aforementioned GUSA.
QuantRx Biomedical Corp. (QTXB), closed Tuesday's trading session at $0.0405, up 125.00%, on 4,624,848 volume with 619 trades. The average volume for the last 60 days is 25,259 and the stock's 52-week low/high is $0.01/$0.09.
La Ronge Gold Corp. (LAR.V)
Today we are highlighting La Ronge Gold Corp. (LAR.V), here at the QualityStocks Daily Newsletter.
La Ronge Gold Corp. is a gold-resource growth and development company whose shares trade on the TSX Venture Exchange. The Company is focusing on the expansion of high-grade gold deposits in the La Ronge Gold Belt in northern Saskatchewan. La Ronge has significant land positions (52,932 Ha. or 131,000 acres) in this region. La Ronge Gold has their corporate headquarters in Vancouver, British Columbia (B.C.).
In addition, La Ronge holds other gold projects located in the Province of Ontario. This includes the Old Cabin Project near Wawa. This property is contiguous to the Island Gold Mine where Richmont Mines recently added a new high grade Inferred Mineral Resources of 508,000 ounces Au at a grade of 10.73 g/t Au.
La Ronge Gold has two gold deposits in the La Ronge Gold Belt. The Company has completed an NI 43-101 Resource Calculation at their flagship Preview SW (PSW) Gold Deposit. They are advancing their Preview SW gold deposit with metallurgical studies underway and economic studies beginning in this second quarter of 2013.
The resources at PSW are 138,100 ounces of gold in the indicated category grading 2.11 grams per tonne gold (0.50 grams per tonne gold cut-off grade), and 257,300 ounces of gold in the inferred category grading 2.09 grams per tonne gold (0.50 grams per tonne gold cut-off grade). The deposit remains open for further expansion and is amenable to open-pit mining.
Yesterday, La Ronge Gold reported on recently completed metallurgical testing of sample materials from the Preview SW deposit in northern Saskatchewan. ALS Metallurgy of Kamloops, B.C., commissioned metallurgical testing to provide a preliminary assessment of the gold recovery potential of two samples of gold-bearing materials from the Preview deposit.
Two samples of mineralized drill core from the Preview SW deposit indicate total gold recovery in concentrate ranging from 90 to 93 percent. A major portion of the gold in the Preview SW Deposit occurs as free gold; it is available for recovery using gravity processes - gravity concentrates capture 52 to 72 percent of the free gold. Sufficiently high-grade flotation-concentrates can undergo production to permit the evaluation of shipping the concentrate to a third-party treatment facility.
La Ronge Gold Corp. (LAR.V), closed Tuesday's trading session at $0.16, down 8.57%, on 43,000 volume. The stock's 52-week low/high is $0.14/$0.37.
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.04, even with yesterday's close, on 1,162,219 volume with 47 trades. The stock’s average daily volume over the past 60 days is 2,029,864, and its 52-week low/high is $0.0275/$0.155.
Advaxis Inc. announced today that the company has filed a Form DEFR14A with the U.S. Securities and Exchange Commission to amend its Proxy Statement Supplement dated May 22, 2013, further revising Proposal No. 3 to now decrease the proposed total number of authorized shares of common stock post-reverse stock split to 25M (in the earlier proxy supplement, the proposed figure was 50M). CEO of ADXS, Thomas A. Moore, noted how the revision is shareholder feedback-driven and underscored that the Board of Directors, as well as the company's management were strongly urging stockholders to vote in favor of the move, as it will position the company to fully execute on capital accumulation and the business plan targets.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Announces Amendment of Proxy Statement Supplement Further Reduction in Share Capital Proposal
Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Advaxis Announces Filing of Proxy Statement Supplement and New Annual Meeting Date
Raptor Resources Holdings Inc. (RRHI)
The QualityStocks Daily Newsletter would like to spotlight Raptor Resources Holdings Inc. (RRHI). Today, The Aristocrat Group Corp. closed trading at $0.0215, off by 2.27%, on 75,000 volume with 5 trades. The stock’s average daily volume over the past 60 days is 76,499, and its 52-week low/high is $0.0002/$0.0395.
Raptor Resources Holdings Inc. was please to announce engagement of Scottsdale, Arizona-based collator of data from hundreds of Small-Cap online Investment Newsletters into one Daily Newsletter Report, QualityStocks, and will henceforth be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs, and on the Message Boards. QualityStocks is dedicated to assisting emerging public companies like RRHI, which is an up and coming publicly traded holdings company focused squarely on mineral resource acquisition, exploration, and development via its subsidiaries, Mabwe Minerals Inc. and TAG Minerals Inc.
Raptor Resources Holdings Inc. (RRHI) is a publicly traded holdings company focused on mineral resource acquisition, exploration, and development. The company currently has two subsidiaries: Mabwe Minerals Inc. (MBMI), a natural resources and hard asset company engaged in the mining and commercial sales of industrial minerals & metals with first focus on barite; and TAG Minerals Inc., a mineral & metal resource acquisition, exploration, and development company with first focus on alluvial surface gold.
Mabwe Minerals has been the focus of the parent company’s efforts the last two years to move into commercial barite production. RRHI shareholders share a common interest with MBMI shareholders in the success of Dodge Mine as the parent company owns 90M shares of MBMI. The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc.
TAG Minerals, along with its indigenous affiliate, TAG Minerals Zimbabwe (Private) Limited, is responsible for alluvial gold production along with the development of greenfield assets targeting bedrock gold and other potential metals & minerals. As MBMI is transitioning into commercial barite production, RRHI will now focus on building assets within TAG Minerals with the intent of moving into commercial production within the next 18 months. TAG Minerals will utilize the latest in Heavy Particle Concentrators (HPC-30/HPC-100) through its relationship with Extrac-TEC whose gold recovery and mineral separation technology captures up to 98% of alluvial gold down to 50 microns. The company is in early stage exploration evaluating potential alluvial sites to ensure they meet the company's criteria for commercial production. Coupled with MBMI's acquisition of WGB Kinsey & Company, TAG Minerals is well positioned to fast track into commercial production once the company has successfully completed its exploratory testing.
RRHI management continues to improve its balance sheet as reflected in the company's SEC 10k filing, including favorable reductions in the company's debt/liabilities and securing 54.4M shares and 14.4M warrants of RRHI from prior employees. The company is committed to growing its asset base in TAG Minerals moving forward. Disclaimer
Raptor Resources Holdings Inc. Company Blog
Raptor Resources Holdings Inc. News:
Raptor Resources Holdings Inc. Announces Engagement of QualityStocks Investor Relations Services
Mabwe Minerals Shareholder Report Card
Raptor Resources Holdings Files SEC Form 10-K, Annual Report
StreamTrack, Inc. (STTK)
The QualityStocks Daily Newsletter would like to spotlight StreamTrack, Inc. (STTK). Today, The Aristocrat Group Corp. closed trading at $0.30, up 50.00%, on 1,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 1,345, and its 52-week low/high is $0.20/$5.00.
StreamTrack, Inc. (STTK), a digital media and technology services company, provides audio and video streaming and advertising services through its RadioLoyalty™ Platform to a global group of internet and terrestrial radio stations, internet radio guides, and other broadcast content providers. The company's platform powers a web-based and mobile player that manages streaming audio and video content, social media engagement, and ad serving.
StreamTrack offers its platform directly to broadcasters and integrates or white labels its technologies with web-based internet radio guides and other web-based content providers. With StreamTrack technology, broadcasters and publishers are able to maximize their revenue while decreasing expenses, while advertisers are provided with a cost-effective means to reach their target audience from one source at scale.
WatchThis™, StreamTrack's patent-pending technology designed to provide web, mobile, and IP television streaming services that are e-commerce enabled within streamed content, could revolutionize the entertainment industry by combining original network content with interactive product placement. Recognizing the convergence of traditional televised advertisement and internet technology, StreamTrack is advancing its WatchThis™ technology to lead the revolution taking place.
StreamTrack is dedicated to continually creating and managing innovative technology products to provide broadcasters and content owners the most advanced solutions available in the marketplace. Fully committed to also increasing and protecting shareholder value, the management team carefully executes operational, development, and marketing programs with the primary aim of maximizing the company's growth potential and profitability. Disclaimer
StreamTrack, Inc. Company Blog
StreamTrack, Inc. News:
StreamTrack Announces Alliance to Potentially Reach Over 300 Million Registered PPTV Users
StreamTrack Announces Operating Results for Second Quarter Fiscal 2013
StreamTrack Announces Stock Ticker Symbol Change to "STTK"
The Aristocrat Group Corp. (ASCC)
The QualityStocks Daily Newsletter would like to spotlight The Aristocrat Group Corp. (ASCC). Today, The Aristocrat Group Corp. closed trading at $0.62, up 34.78%, on 2,176,495 volume with 543 trades. The stock’s average daily volume over the past 60 days is 199,042, and its 52-week low/high is $0.21/$1.25.
The Aristocrat Group Corp. (ASCC) is a brand management company focused on providing premiere luxury goods through continual innovation. Luxuria Brands, a subsidiary of The Aristocrat Group, has been established to identify and promote unique brands that have mass market appeal across a diverse demographic.
Luxuria Brands is primarily concentrated on distilled spirits industries, with an initial focus on Vodka branding and marketing. The worldwide distilled spirits market is currently worth about $263 billion. In the U.S. alone, Vodka sales between 2004 and 2009 grew 25% from 13.9 million cases to 58.4 million cases. The clear liquor now accounts for almost a third of all distilled spirits consumed and continues to rise in popularity.
The Aristocrat Group is also pursuing opportunities in the women’s lifestyle industry. The World Bank recently estimated that the earning power of women will reach $18 trillion by 2014, which is twice the estimated 2014 GDP of China and India combined. The Aristocrat Group is working to bring fresh, innovative prenatal and postpartum solutions to women who are looking for a more comprehensive approach to wellness.
The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. The company aims to take a leadership position in multiple growing markets that offer opportunities for partnership, sponsorship, and brand awareness activities. The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. Disclaimer
The Aristocrat Group Corp. Company Blog
The Aristocrat Group Corp. News:
ASCC Declares Market Conditions Ideal for Upcoming Vodka Launch
ASCC Formulates Plans to Capitalize on Successful Vodka Launch
ASCC Unveils Debut Spirits Brand RWB Vodka
Therapeutic Solutions International develops, produces and markets technologies and therapeutic modalities to treat and prevent common neurologic, sleep and temporomandibular disorders. The company has signed a letter of intent under which it will receive from S4S (UK) Limited the exclusive U.S. distribution rights to market patented and FDA-cleared titratable sleep appliance hardware.
“This letter of intent with TSI is one more forward step in our ever growing relationship,” Matt Everatt, technical director of S4S (UK) stated in the press release. “We are very excited about TSI exclusively distributing our sleep appliance hardware in the U.S. and look forward to completing a definitive agreement.”
Oral appliances help maintain an open airway during sleep, promoting adequate air intake. The appliances can be used alone or in combination with other treatments for sleep-related breathing disorders. Acquiring the rights to distribute the sleep appliance hardware provides a doorway for TSOI to enter into the dental sleep market and the change to enhance its nationwide presence.
“Our alliance with S4S has provided us an opportunity to introduce a new product into the U.S. marketplace,” Tim Dixon, CEO of TSOI stated. “We have been working on this collaboration with S4S and look forward to a long and rewarding relationship. According to the American Academy of Dental Sleep Medicine, ‘More than 18 million Americans have sleep apnea, and many are not receiving treatment’: We intend to play a role in the treated and untreated with our sleep appliance hardware.
For more information visit www.therapeuticsolutionsint.com
LifeVantage Corporation is a science-based nutraceutical company. The company makes products aimed at transforming wellness and anti-aging both internally and externally by dramatically reducing oxidative stress at the cellular level. It is the maker of Protandim, the Nrf2 Synergizer dietary supplement, TrueScience Anti-Aging Cream and LifeVantage Canine Health.
The company announced today that it has expanded its direct selling business north of the border into Canada. It will now be doing business in the United States, Canada, Mexico, Japan, Australia and Hong Kong. LifeVantage had already been selling Protandim, the Nrf2 Synergizer and TrueScience Anti-Aging Cream on a limited basis in Canada to preferred customers.
But now it is offering the opportunity to participate in its business for interested Canadian customers. Effective June 5, LifeVantage will be accepting applications for independent distributors in Canada and will begin paying commissions earned later in the month of June. The company believes this makes sense based on the past two years of solid demand from Canadian customers for its products. Its goal is to increase operations globally in places that have long-term growth opportunities.
Canada certainly fits the bill as a growth opportunity for network marketers. The World Federation of Direct Selling Associations reported a market of approximately 700,000 distributors and sales of $2.2 billion in 2011 in the country. LifeVantage will begin by continuing to offer Protandim and TrueScience to customers and will offer its LifeVantage Canine Health product in the future.
For additional information about LifeVantage and its line of nutraceutical products, please visit the company’s website at www.lifevantage.com
Pixelworks, Inc., creator, developer and marketer of video display processing technology for digital video applications, announced today that is cutting edge video display will soon be featured in Tablets and Ultrabooks. The company will demonstrate its technology for the highest quality video at invitation-only meetings at this year’s COMPUTEX TAIPEI. Specifically, Pixelworks’ demonstrations will be on Windows 8™ Tablets and Ultrabooks based on Intel’s 4th generation Core™ processors.
Users are beginning to demand the highest image quality for their movies, photos and video games on every screen that they choose to consume media. Utilizing an innovative new process, Pixelworks is able to bring the top flight display quality to Tablets and Ultrabooks that is traditionally reserved for large screens.
“Pixelworks has always been about video quality, and we believe that every screen, especially the highest resolution Tablets and Ultrabooks, are ideal platforms for the very best video processing technology,” said Graham Loveridge, Sr. Vice President of Marketing at Pixelworks.
To obtain an invitation to the Pixelworks suite at COMPUTEX, or for additional information about Pixelworks’ products, including the company’s newest video display processor solutions for Tablets and Ultrabooks, please contact your local Pixelworks office.
For further information, please visit www.pixelworks.com.
sTec, a global provider of enterprise-class, solid-state storage solutions, has expanded its Asia-Pacific (APAC) operations with three additions to its regional sales and support team. Collectively, the three new additions contribute more than 50 years of sales, marketing and management experience in the enterprise-storage industry.
The company named Michael Burnie as senior vice president of sales for APAC. Burnie has more than 25 years of enterprise-storage experience, formerly serving as vice president and general manager of APAC operations with Isilon Systems. He also previously worked with NetApp as managing director for that company’s Australia, Southeast Asia and India operations.
sTec appointed Shigeo Kimura and George Thomasas country managers for Japan and India, respectively.Kimura and Thomas will directly report to Burnie, who is based in the sTec(R) Malaysia office.
Kimura previously worked as executive vice president of sales for APC Japan, a provider of data center solutions. Prior to APC Japan, Kimura was senior director of the semiconductors division at Philips Japan and served in various sales management positions with Dell, in Japan.
Thomas has more than 20 years of experience in the IT industry, most recently serving as a director at Rivendale Software, where he focused on enterprise information protection. He also previously worked as country manager for India and the South Asian Association for Regional Cooperation (SAARC) at Tibco Software, as well as managing director for India and SAARC at NetApp.
“We’ve had great success in APAC over the years developing relationships with many of the region’s top enterprise-systems players,” Nader Milani, managing director of sTec Malaysia stated in the press release. “With the additional focus and capable team of Shigeo and George, led by Michael, we’ll be well poised to further build on our success throughout the region.”
For more information visit www.stec-inc.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) Announces Amendment of Proxy Statement Supplement Further Reduction in Share Capital Proposal
- Consorteum Holdings, Inc. (CSRH) Enters Partnership Agreement With KO Entertainment, Inc.
- Cardium Therapeutics, Inc. (CXM) Announces Generx Publication In Molecular Therapy
- DoMark International, Inc. (DOMK) Develops New Product for $2.3 Billion iPad Accessories Market
- GNCC Capital, Inc. (GNCP) Reaches Agreement to Acquire White Hills Gold Properties
- GlobalWise Investments, Inc. (GWIV) Adds Toshiba Business Solutions AZ/CO as New Channel Sales Partner
- International Stem Cell Corp. (ISCO) Initiates IND-Enabling Study in Parkinson's Disease Program
- Loans4Less.com, Inc. (LFLS) CEOCFO Magazine Interview Highlights Solid Market Position
- Low Carbon Technologies International, Inc. (LWCTF) Plans to Announce 6 Month YTD Financials
- Mabwe Minerals Inc. (MBMI) Announces Engagement of QualityStocks Investor Relations Services
- Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
- Rainbow Coral Corp. (RBCC) to Drive Growth Through Personalized Medicine
- Raptor Resources Holdings Inc. (RRHI) Announces Engagement of QualityStocks Investor Relations Services
- Solar Wind Energy Tower, Inc. (SWET) CEO Featured in Exclusive QualityStocks Interview
- StreamTrack, Inc. (STTK) Announces Alliance to Potentially Reach Over 300 Million Registered PPTV Users
- The Aristocrat Group Corp. (ASCC) Declares Market Conditions Ideal for Upcoming Vodka Launch
- The Guitammer Company Inc. (GTMM) Goes Supersonic!
- VentriPoint Diagnostics Ltd. (VPTDF) Announces New Vice-President of Sales and Marketing
- VistaGen Therapeutics, Inc. (VSTA) and Duke University Publish Results on Production of Functional 3D Human Heart Tissue